Cargando…

Instantaneous mutation rate in cancer initiation and progression

BACKGROUND: Cancer is one of the leading causes for the morbidity and mortality worldwide. Although substantial studies have been conducted theoretically and experimentally in recent years, it is still a challenge to explore the mechanisms of cancer initiation and progression. The investigation for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shuhao, Klebaner, Fima, Zhang, Xinan, Tian, Tianhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249718/
https://www.ncbi.nlm.nih.gov/pubmed/30463617
http://dx.doi.org/10.1186/s12918-018-0629-z
_version_ 1783372799759351808
author Sun, Shuhao
Klebaner, Fima
Zhang, Xinan
Tian, Tianhai
author_facet Sun, Shuhao
Klebaner, Fima
Zhang, Xinan
Tian, Tianhai
author_sort Sun, Shuhao
collection PubMed
description BACKGROUND: Cancer is one of the leading causes for the morbidity and mortality worldwide. Although substantial studies have been conducted theoretically and experimentally in recent years, it is still a challenge to explore the mechanisms of cancer initiation and progression. The investigation for these problems is very important for the diagnosis of cancer diseases and development of treatment schemes. RESULTS: To accurately describe the process of cancer initiation, we propose a new concept of gene initial mutation rate based on our recently designed mathematical model using the non-constant mutation rate. Unlike the widely-used average gene mutation rate that depends on the number of mutations, the gene initial mutation rate can be used to describe the initiation process of a single patient. In addition, we propose the instantaneous tumour doubling time that is a continuous function of time based on the non-constant mutation rate. Our proposed concepts are supported by the clinic data of seven patients with advanced pancreatic cancer. The regression results suggest that, compared with the average mutation rate, the estimated initial mutation rate has a larger value of correlation coefficient with the patient survival time. We also provide the estimated tumour size of these seven patients over time. CONCLUSIONS: The proposed concepts can be used to describe the cancer initiation and progression for different patients more accurately. Since a quantitative understanding of cancer progression is important for clinical treatment, our proposed model and calculated results may provide insights into the development of treatment schemes and also have other clinic implications.
format Online
Article
Text
id pubmed-6249718
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62497182018-11-26 Instantaneous mutation rate in cancer initiation and progression Sun, Shuhao Klebaner, Fima Zhang, Xinan Tian, Tianhai BMC Syst Biol Software BACKGROUND: Cancer is one of the leading causes for the morbidity and mortality worldwide. Although substantial studies have been conducted theoretically and experimentally in recent years, it is still a challenge to explore the mechanisms of cancer initiation and progression. The investigation for these problems is very important for the diagnosis of cancer diseases and development of treatment schemes. RESULTS: To accurately describe the process of cancer initiation, we propose a new concept of gene initial mutation rate based on our recently designed mathematical model using the non-constant mutation rate. Unlike the widely-used average gene mutation rate that depends on the number of mutations, the gene initial mutation rate can be used to describe the initiation process of a single patient. In addition, we propose the instantaneous tumour doubling time that is a continuous function of time based on the non-constant mutation rate. Our proposed concepts are supported by the clinic data of seven patients with advanced pancreatic cancer. The regression results suggest that, compared with the average mutation rate, the estimated initial mutation rate has a larger value of correlation coefficient with the patient survival time. We also provide the estimated tumour size of these seven patients over time. CONCLUSIONS: The proposed concepts can be used to describe the cancer initiation and progression for different patients more accurately. Since a quantitative understanding of cancer progression is important for clinical treatment, our proposed model and calculated results may provide insights into the development of treatment schemes and also have other clinic implications. BioMed Central 2018-11-22 /pmc/articles/PMC6249718/ /pubmed/30463617 http://dx.doi.org/10.1186/s12918-018-0629-z Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Software
Sun, Shuhao
Klebaner, Fima
Zhang, Xinan
Tian, Tianhai
Instantaneous mutation rate in cancer initiation and progression
title Instantaneous mutation rate in cancer initiation and progression
title_full Instantaneous mutation rate in cancer initiation and progression
title_fullStr Instantaneous mutation rate in cancer initiation and progression
title_full_unstemmed Instantaneous mutation rate in cancer initiation and progression
title_short Instantaneous mutation rate in cancer initiation and progression
title_sort instantaneous mutation rate in cancer initiation and progression
topic Software
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249718/
https://www.ncbi.nlm.nih.gov/pubmed/30463617
http://dx.doi.org/10.1186/s12918-018-0629-z
work_keys_str_mv AT sunshuhao instantaneousmutationrateincancerinitiationandprogression
AT klebanerfima instantaneousmutationrateincancerinitiationandprogression
AT zhangxinan instantaneousmutationrateincancerinitiationandprogression
AT tiantianhai instantaneousmutationrateincancerinitiationandprogression